Unsuspected allies: Chemotherapy teams up with immunity to fight cancer

Chemotherapy has been a standard treatment for cancer for the past several decades and has long been suspected to cause systemic immune suppression. However, in recent years it has become clear that the immune status of a patient is an independent prognostic factor for chemotherapeutic efficacy, and that T‐cell‐mediated responses actively contribute to the tumor destruction triggered by some chemotherapeutic agents. In this respect, the induction of immunogenic cell death by these compounds appears to be crucial. In this issue of the European Journal of Immunology, a study by Hannesdóttir et al. [Eur. J. Immunol. 2013. 43: 2718–2729] demonstrates a crucial role for the IFN signaling molecule STAT1 during doxorubicin and Lapatinib treatment of HER2/Neu‐driven mammary carcinomas. The genotoxic anthracycline doxorubicin causes immunogenic cancer cell death and is expected to depend on the immune system, but the dual ErbB2/HER2/Neu and ErbB1/EGFR inhibitor Lapatinib also turns out to cause immune reactivity. Although CD8+ T cells are partially involved in this phenomenon, doxorubicin, and Lapatinib also affect the myeloid infiltrate (i.e. tumor‐associated macrophages and monocytes) in tumors. In this Commentary, we place these findings in the context of current knowledge and propose new avenues for future research.

[1]  P. De Baetselier,et al.  Tumor‐induced myeloid‐derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T‐cell activation events , 2013, European journal of immunology.

[2]  Nina Daschil,et al.  Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response , 2013, European journal of immunology.

[3]  P. van Endert,et al.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. , 2013, Immunity.

[4]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[5]  M. Serrano,et al.  In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation and Pro-Tumoral Activities , 2012, PloS one.

[6]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[7]  J. Casanova,et al.  Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes , 2012, Current Opinion in Immunology.

[8]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Jonkers,et al.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system , 2012, Nature Medicine.

[10]  L. Zitvogel,et al.  The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.

[11]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[12]  Alexandros Nikolaou,et al.  Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. , 2011, Immunobiology.

[13]  S. Loi,et al.  Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. , 2011, Cancer research.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  W. Muller,et al.  Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation , 2011, Cell cycle.

[16]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[17]  Lothar Hennighausen,et al.  Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. , 2010, Neoplasia.

[18]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[19]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[20]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[21]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[22]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[23]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[24]  C. Marth,et al.  Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Dr Stephen J. Lane.  The Mononuclear Phagocyte , 1995, Clinical Immunotherapeutics.

[27]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.